Latest news with #Radixact
Business Upturn
01-07-2025
- Health
- Business Upturn
Cancer Treatment Gets a Boost with Radixact System in Mumbai
A Mumbai-based hospital, has introduced the Radixact® Treatment Delivery System, a next-generation radiation therapy technology that offers real-time imaging and adaptive precision. The system aims to improve cancer treatment outcomes by targeting tumors more accurately while minimizing damage to healthy tissue. By Riddhima Jain Published on July 1, 2025, 16:51 IST A Mumbai hospital has introduced the Radixact® Treatment Delivery System, a new radiation therapy technology aimed at improving accuracy in cancer treatment and reducing harm to healthy tissue. The system combines real-time imaging with adaptive targeting, allowing doctors to adjust radiation delivery as the patient's body moves—such as during breathing. A built-in CT scanner helps ensure the tumor remains accurately targeted throughout the procedure. According to the hospital, this upgrade is part of ongoing efforts to improve cancer care through more precise, individualized treatment. The system is capable of treating a variety of cancers and is designed to deliver higher doses of radiation with fewer side effects. The hospital has also invested in genomic testing and precision oncology infrastructure. A 500-gene cancer panel is being used to support more tailored treatment plans based on a tumor's genetic profile. precision and efficiency. Dr Santosh Shetty, Executive Director and CEO of Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute said, 'At Kokilaben Hospital, we are constantly pushing the boundaries of medical innovation to ensure our patients receive the most advanced and effective treatment. The adoption of the globally acclaimed Radixact® system marks a major leap forward in our commitment to delivering world-class cancer care. As a centre that continues to be recognized for its leadership in oncology, we are proud to bring one of the most sophisticated radiation technologies to India. This upgrade reaffirms our dedication to adopting global standards that improve both clinical outcomes and quality of care .' The adoption of the Radixact system comes amid a growing cancer burden in India. Health experts say timely access to accurate diagnosis and targeted treatment remains a challenge for many patients, and that such technologies could help improve survival rates and reduce complications. Ahmedabad Plane Crash
Newsweek
28-04-2025
- Health
- Newsweek
New Study Shows Promise for Cancer Patients Avoiding Surgery
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A promising new study presented at the American Association for Cancer Research's annual meeting shows that immunotherapy could help many cancer patients avoid surgery. Researchers found that 92 percent of patients who received only an immune-based treatment remained cancer-free two years later. Why It Matters The findings suggest that for some cancers, surgery and its difficult recovery may not always be necessary. This could dramatically change standard treatment approaches, offering a less invasive option with fewer long-term side effects for patients. Accuray Radixact machine with patient being positioned and accompanied by therapist on August 26-27 in Geneva, Swiss Confederation. Accuray Radixact machine with patient being positioned and accompanied by therapist on August 26-27 in Geneva, Swiss to Know The study, published in the New England Journal of Medicine, explored whether immune checkpoint inhibitors could help shrink tumors without the need for surgery. These drugs work by boosting the body's natural ability to detect and destroy cancer cells. Among patients with rectal cancer, a previous study found that all 42 participants who received the therapy remained cancer-free after four years. In this new study, which included patients with other types of cancers, such as colon, esophageal, stomach, and gastroesophageal junction cancers, 92 percent had no signs of disease after two years. Maureen Sideris, 71, was one of the patients who benefited from the new approach, Time reported. Diagnosed with gastroesophageal junction cancer, she initially faced the prospect of major surgery, chemotherapy, and radiation. Instead, she opted into the experimental immune-based treatment, receiving monthly infusions for nine months. Two years later, her cancer remains undetectable. Dr. Andrea Cercek of Memorial Sloan Kettering Cancer Center, who led the study, noted that even patients with more advanced Stage III cancers responded well. The treatment was effective even when cancer had spread to nearby lymph nodes, offering hope for a broader group of patients. Researchers plan to follow patients for a longer period to determine if the benefits translate into higher survival rates. They are also investigating why some patients did not respond in hopes of refining the treatment even further. The checkpoint inhibitor used, dostarlimab, has already been fast-tracked by the FDA for certain cancers with specific genetic mutations. What People Are Saying Dr. Andrea Cercek, Memorial Sloan Kettering Cancer Center to TIME: "Therapy like this can lead to significant tumor downstaging and improve patients' quality of life." Maureen Sideris, study participant to TIME: "The infusions were the easiest part. I'm so grateful I could avoid surgery." What Happens Next Researchers are continuing trials to determine the long-term effectiveness of this treatment across different cancer types and stages. If results remain strong, immunotherapy could become a standard first-line option for many patients, reshaping cancer care for years to come.
